TNFRSF10C (tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain) Blocking Peptide (the N terminal of protein) (100ug)

Supplier: Aviva Systems Biology Incorporated

0 reviews | Write a Review Pencil

Description
Additional Information

This is a synthetic peptide designed for use in combination with anti-TNFRSF10C antibody (Catalogue #: AVARP02039_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Presku:	AAP30623
Size:	100 ug
Weight:	25kDa
Gene:	8794
Format:	Lyophilized powder
Target:	TNFRSF10C is the receptor for the cytotoxic ligand TRAIL. TNFRSF10C lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. TNFRSF10C may protect cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alternative names:	CD263; DCR1; LIT; MGC149501; MGC149502; TRAILR3; TRID